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Abstract
In this essay I suggest that the major difficulty in producing effective anti-cancer vaccines lies in the
fact that most cancers have little immunogenicity because of a basic paucity of tumor-specific
antigenicity. The lack of antigenicity, despite extensive genomic instability, could be explained if
most tumor mutations occur in silenced genes. A further problem is that an immune reaction
against tumor antigens, especially in moderate or low amount, may be stimulatory rather than
inhibitory to tumor growth.
It is now almost half a century since the overthrow of Ehr-
lich's doctrine of "horror autotoxicus" and the general
acceptance of the contrary idea that animals can indeed be
immunized against the growth of a transplanted syn-
geneic cancer. Why then is it that, despite nearly 50 years
of intense investigation, attempts to use the immune reac-
tion as a tool against cancer have, with the exception of
bladder cancer, met with only moderate success? What is
the realistic prospect that the next 50 years will see an
improvement in this dismal state of affairs? Many investi-
gators, myself included, have a large vested interest in the
field of cancer immunology and will be reluctant to enter-
tain any discouraging viewpoint, but the actual facts are, I
believe, discouraging.
Background
As a part of the original demonstration that syngeneic
anticancer immunity is possible, it was shown that,
among sarcomas induced in mice by a hydrocarbon, each
tumor, when transplanted, could arouse an inhibitory
immune reaction against itself [1]. However, it also
became very clear that each tumor was antigenically
unique, even if each had been induced by identical means
in one and the same animal; although cross-reactions
were reported, these were the exception [2,3]. Since it is
probable that the immunogenicity was caused by the
mutations induced by the mutagenic carcinogen, it was
obvious that these chemicals produced a different spec-
trum of mutations in each tumor and with very little over-
lap. Consequently, one had to conclude that any of a vast
array of possible mutations could be found in phenotypi-
cally similar cancers, a not impossible idea. However, it
was also clear that none of the carcinogen-induced muta-
tions, at least among those identified by their resulting
antigenicity, could be considered essential or causative for
the induction of the cancer.
Not surprisingly, although sarcomas induced by the same
concentration of oncogen displayed a wide range of
immunogenic strengths, there was found to be a positive
statistical correlation between the strength of the immu-
nogenicity and the concentration of the inducer [4,5].
Unfortunately, this relationship means that tumors
induced by low concentrations of inducer, or that arise
without obvious cause, tend to have either a very low or a
nondetectable immunogenicity [6]. It is my hypothesis, as
presented in this essay, that the paucity of immunogenic-
ity reflects, for the most part, a basic lack of tumor-specific
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antigenicity rather than a blocking or suppression of an
immune response.
Immunosurveillance
It has been argued that the apparent general lack of tumor
immunogenicity may be an artifact caused by immune
selection for nonimmunogenic tumor variants. Perhaps
most tumors, in accord with the immunosurveillance
hypothesis, are really highly immunogenic and what we
see is actually a small surviving, relatively non-immuno-
genic, highly selected subpopulation. This popular con-
cept, judged by at least four types of evidence, is probably
incorrect and thus cannot account for the paucity of
tumor immunogenicity.
Firstly, immunological depression by any means usually
has little if any facilitating effect on oncogenesis. Thus,
chemical oncogenesis is not obviously altered by immun-
odepression [7]; the tumor immunogenicity and/or the
degree of immune depression must be very carefully
titrated in order to see any effect of immune depression,
either positive or negative [8,9]. Both within and without
the immunologically isolated environment of intraperito-
neal diffusion chambers, nonimmunogenic tumors are
commonly induced [10,11]. Furthermore, chemically-
induced tumorigenesis may actually be lessened, not
increased, in immunologically crippled, germ-free nude
mice as compared with their essentially normal hetero-
zygous nude controls [8].
Secondly, often a minute dosage of highly immunogenic
transplanted cancer cells may grow when a somewhat
larger inoculum fails [12]; this "sneaking through phe-
nomenon", which can occur even in specifically immu-
nized animals, again suggests that small incipient tumors
could probably not be effectively surveyed.
Thirdly, even highly immunogenic hydrocarbon-induced
sarcomas may fail to induce immunity if the tumor is left
undisturbed in situ, so how could more ordinary tumors
of lesser immunogenicity kindle a surveillance mecha-
nism? In fact, to arouse an inhibitory immunity in the pri-
mary autochthonous host is difficult and, at least with
hydrocarbon-induced sarcomas, requires repeated immu-
nizations [13]. More often the challenge tumor, inocu-
lated back into the animal in which it had originated,
grew better than it did in other animals of the same strain,
ie., better than it did in animals that had never before
been exposed to that tumor [14,15]. This latter observa-
tion is best interpreted by the immunostimulation
hypothesis [16] which I will now discuss.
Immunostimulation
As compared with normal spleen cells, low proportions of
spleen cells from immunized mice stimulated rather than
inhibited the proliferation of admixed tumor cells when
the mixture was injected subcutaneously. In this so called
"Winn test" [17], larger proportions of immune spleen
cells inhibited the growth of the same admixed tumor
cells. As previously discussed, most tumors, arising from
low concentrations of inducing agents, are expected to
have little immunogenicity. The little immune response
these tumors might engender would be expected, judging
by these Winn test results, to stimulate rather than inhibit
tumor growth. This was emphatically confirmed in a vari-
ety of extensive studies which showed, among other
things, that a newly induced in situ mouse tumor, mesen-
chymal or epithelial, was stimulated to grow faster (had a
shorter latency) if it could engender an immune response
[8,11]. Even tumors that subsequently were shown to be
highly immunogenic usually grew faster than tumors of
little or no immunogenicity when the tumors were left
undisturbed in their primary hosts [11]. Therefore, when
immunodepression does appear to favor oncogenesis,
this result, in many cases, is probably not because an
immunological inhibitor to tumor growth has been
reduced, but rather because the immune reaction has
been depressed to a more stimulatory level [18]. Also, the
possibility of doing harm by attempts at immunotherapy
need to be carefully cosidered. For more extensive reviews
and other evidences of tumor immunostimulation see
[8,11,18,19].
The fact that a moderate tumor-specific immune reaction
apparently favors the growth of an undisturbed in situ
tumor, seems adequate to rule out any immunosurveil-
lance of incipient cancers. Thus, the paucity of tumor
immunogenicity is probably not caused by immunoselec-
tion. Rather, most types of tumor are apparently created de
novo with little tumor-specific immunogenicity unless the
tumors were induced by a large concentration of carcino-
gen and/or by an oncogenic virus. In fact, at least among
hydrocarbon-induced mouse sarcomas, whatever little
immune selection there may be apparently favors, rather
than inhibits, the proliferation of a nacsent tumor.
Role of Mutation
If cancer is based, in accord with the current paradigm,
upon somatic mutations, why would most tumors have so
little specific immunogenicity? While this question has
many possible answers, it seems to me that, in the absence
of immunoselection, there are two prime possibilities:
either the somatic mutation idea of carcinogenesis is
incorrect and/or the tumor mutations occur, for the most
part, in silenced genes that are incapable of producing an
antigenic product.
The hypothesis that the somatic-mutation paradigm is
incorrect has been advanced over a number of years by a
number of brave heretics [20-26]. They suggest that theCancer Cell International 2005, 5:25 http://www.cancerci.com/content/5/1/25
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mutations seen in neoplasia may not be causative; they
are, instead, probably incidental or secondary. Primary
epigenetic rather than genetic changes are postulated to
result in the neoplastic phenotype. This hypothesis has
the great virtue, as compared with the mutational para-
digm, in that a tumor's reversion to a normal phenotype
can be more easily understood. Reversion to a normal
phenotype is indeed observed in a variety of laboratory
experiments as well as in some clinical settings [26,27].
The real cause of most cancers is postulated by the heretics
to reside in disrupted cell to cell signaling or some other
epigenetic alteration which changes the spectrum of gene
expression to produce a neoplastic phenotype. The many
cogent arguments put forth by the heretics, entirely apart
from any considerations of immunogenicity, have been
well reviewed elsewhere [20-26]. However, these ideas of
an epigenetic etiology fit well with the facts concerning
the general lack of immunogenicity of cancers and could
help to explain why immunity has not as yet lived up to
its expected diva role in cancer therapy and prevention.
My personal view of the intimate details of carcinogenesis
incorporates two suppositions, for each of which there is
supporting experimental evidence. I will therefore, for
purposes of this discussion, consider both of the follow-
ing statements to be correct. The first is that DNA repair is
defective or nonexistent in untranscribed or silenced
genes [28]. Secondly, DNA mutation and repair both
require cellular proliferation [29].
Sonnenschein and Soto have suggested that proliferative
activity, rather than quiescence, is the default condition of
cells [20]; thus the natural impulse of free-living cells to
proliferate is, in a multicellular animal, actively regulated
by aspects of the multicellular environment. It seems log-
ical, therefore, to propose that the abnormal proliferative
activity in a cancer requires that certain suppressor genes,
especially those that normally, in a post-embryonic ani-
mal, suppress embryonic development and/or wound
healing, be silenced. My view of carcinogenesis depends,
as I have said, upon the assumption that DNA damage in
untranscribed genes is not repaired [28]. Therefore, it
seems reasonable to assume that, over time in a tumor,
mutations might tend to accumulate in any silenced gene
or in non-coding segments of a gene.
The picture that emerges from these considerations is that
neoplasia is probably caused by the reexpression of prolif-
eration-enhancing development or wound-healing genes
that, outside of a neoplasm, would usually be expressed
only in embryonic life or during wound healing. Such
reexpression, indeed overexpression, now as oncogenes,
could be caused by either interference with communica-
tion between the oncogene and the appropriate suppres-
sor gene or by the actual silencing of the suppressor gene
by either mutation or, perhaps more commonly, by epige-
netic influences. Mutations that may have occurred in the
development genes might often be repaired, if and when
these genes were reexpressed as oncogenes within a prolif-
erating neoplasm. Since the oncogene's function is to
drive the cancer, any mutations in these genes would
probably be highly selected to retain the gene's normal or
near normal function; there might thus be selection to
produce only normal or near normal product, a product
that might then be only minimally, if at all, immuno-
genic. Alternatively, any mutations that did occur among
the oncogenes might not produce immunogenicity if the
products of such mutations were not found on the cell
surface.
Recapitulation
Thus, my thesis is that most  of the mutations actually
found in a neoplasm would probably not be among the
reexpressed proliferation-stimulating oncogenes, but
would be among those suppressor genes that were newly
silenced either during or after transformation and that
remained silenced, unexpressed, and unrepaired through-
out the life of the tumor. Because these suppressor genes
had been silenced, their mutations would probably not
result in new antigens.
To recapitulate, an important corollary of the previous
discussion is the conclusion that the mutations that are
identified by their associated antigens, are seldom cancer-
inducing, but are random and incidental. The genes that
actually drive the neoplasm, the so-called oncogenes, are
embryonic development or wound-healing genes that are
reexpressed and overexpressed in a tumor. Being highly
selected in the tumor for essentially normal functions, the
reexpression of these genes, even when mutated, might
not produce new antigens, especially if the oncogene
products did not appear on the cell surface. Mutations
that occur in silenced suppressor genes go unrepaired, but
because silent unexpressed genes have no product, these
mutations also should fail to give rise to antigens. Thus,
my view of carcinogenesis suggests that there are usually,
with few exceptions, no mutations in the carcinogenic
process that can produce new antigens unless a virus or an
unrealistically high concentration of oncogen is involved.
Mutations, induced by high concentrations of a chemical
carcinogen do give rise to immunogenicity and thus they
presumably occur in expressed genes, but, as already
stated, such mutations are apparently not directly related
to etiology and are usually unrealistic laboratory con-
structs.
In sum, the dismal record of the attempts to utilize anti-
tumor immunity in the clinic seems entirely consistent
with the idea that cancer is a disease based most often
upon the silencing of suppressor genes, either by muta-Cancer Cell International 2005, 5:25 http://www.cancerci.com/content/5/1/25
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tion or by epigenetic means. The epigenetic pathways may
be the more frequent. The postulated, as well as demon-
strated, paucity of antigen-producing mutations in the
expressed genes of most cancers, plus the lack of anti-
genicity that would result from mutations that might arise
in the silenced suppressor genes, explains the basic pau-
city of tumor-specific immunogenicity. Furthermore, the
little tumor immunogenicity that may exist usually pro-
duces a reaction that is stimulatory, not inhibitory, to
tumor proliferation.
Although there is certainly a role for immune suppressor
cells and other blocking factors [30], in this essay I have
suggested that the major difficulty lies in the fact that most
cancers have little immunogenicity because of a basic lack
of tumor-specific antigenicity. What weak antigens a
tumor may have are usually tumor specific rather than
tumor-type specific. The tissue-specific antigens involved
in autoimmune reactions and the "carcino-embryonic
antigens" are important realities, but have been difficult
to utilize to any great extent in cancer prevention or ther-
apy, probably in large part because of the powerful natural
tolerance to such antigens. Perhaps further research will
reveal ways to use the autoimmune mechanism against
cancers that arise in disposible organs such as the prostate
or the mammary gland where tumor specificity might be
less important and organ specificity might be sufficient.
If my view of the carcinogenic process is correct, the utility
of immune mechanisms in the "war on cancer" seems
likely to remain, dispite some minor triumphs, rather dis-
mal. However, the success of intravesicular BCG to treat
carcinoma of the bladder offers hope [31]. There have also
been encouraging reports about the probable immuno-
genicity of cutaneous melanoma [32,33]. Dispite my pre-
viously expressed view that immunosurveillance of cancer
is unlikely, there is one observation that deserves special
mention. It has long been known that cancer occurs with
greatly increased frequency in patients who undergo pro-
longed immunodepression to facilitate kidney transplan-
tation. The increased incidence is not general, but is
largely confined to tumors of the lymphoid system or of
the skin [34]. The excess of lymphoid tumors could be
easily considered the ultimate consequence of compensa-
tory hyperplasia in the damaged immunological organ,
but the excess of skin tumors is more likely to have a direct
immunological basis, either decreased surveillance or
increased immunostimulation by the impaired immune
mechanism. In either case, the fact that the excess tumor
incidence is largely confined to the skin suggests that skin
tumors may be unusually antigenic and/or the skin is an
unusally active immunological organ.
My view of the very complex interaction of cancer and the
immune reaction is certainly simplistic and perhaps
overly pessimistic, but it may, I am afraid, capture the
essence of the problem.
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